Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival

Journal of Clinical Oncology

Volumn 18, Issue 1, 2000, Pages 87-93

  Mackay, H J ^a   Cameron, D ^a   Rahilly, M ^a   Mackean, M J ^a   Paul, J ^a   Kaye, S B ^a   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0033987743     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.1.87     Document Type: Article

References (44)

1. Ursin G, Bernstein L, Pike MC: Breast cancer. Cancer Surv 20:241-264, 1994
2. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:71-85, 1992
3. Smith IE, Al Moundhri M: Primary chemotherapy in breast cancer. Biomed Pharmacotherapy 52:116-121, 1998
4. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
5. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
6. Ellis P, Smith I, Ashley S, et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16:107-114, 1998
7. Bonadonna G, Valagussa P, Brambilla C, et al: Preoperative chemotherapy in operable breast cancer. Lancet 341:1485, 1993
8. Makris A, Powles TJ, Dowsett M, et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3:593-600, 1997
9. Rozan S, Vicent-Salomon A, Zafrani B, et al: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79:27-33, 1998
10. Chevillard S, Lebeau J, Pouillart P, et al: Biological and clinical significance of concurrent p53 gene alterations, mdr1 gene expression, and s-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471-2478, 1997
11. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: A meta-analysis of MDR/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917-931, 1997
12. Honkoop AH, van Diest PJ, de Jong JS, et al: Prognostic role of clinical, pathological, and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621-626, 1998
13. MacGrogan G, Mauriac L, Durand M, et al: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTp. Br J Cancer 74:1458-1465, 1996
14. Brown R, Hirst GL, Gallagher WM, et al: hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 15:45-52, 1997
15. Drummond JT, Anthoney A, Brown R, et al: Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271:19645-19648, 1996
16. Fink D, Aebi S, Howell SB: The role of DNA MMR in drug resistance. Clin Cancer Res 4:1-6, 1998
17. Strathdee G, MacKean M, Illand M, et al: A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18:2335-2341, 1999
18. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci 95:6870-6875, 1998
19. Durant S, Morris M, Illand M, et al: Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of MMR genes. Current Biol 9:51-54, 1999
20. Fink D, Nebel S, Norris PS, et al: The effect of different chemotherapeutic agents on the enrichment of DNA MMR-deficient tumour cells. Br J Cancer 77:703-708, 1998
21. Friedman HS, Johnson SP, Dong Q, et al: Methylator resistance mediated by MMR deficiency in a glioblastoma multiforme xenograft. Cancer Res 57:2933-2936, 1997
22. Loeb LA: Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063, 1994
23. Thibodeau SN, French AJ, Roche PC, et al: Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in MMR genes. Cancer Res 56:4836-4840, 1996
24. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47, 1994
25. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
26. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
27. Bates S, Vousden KH: p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6:12-19, 1996
28. Oren M: Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 5:221-227, 1994
29. Koechli OR, Schaer GN, Seifert B, et al: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 344:1647-1648, 1994
30. Makris A, Powles TJ, Allred C, et al: P53 mutation and chemosensitivity in breast cancer patients. Eur J Cancer 31A:668, 1995 (abstr s140)
31. Hayward JL, Carbone PP, Heusen JC, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298, 1977
32. Mackean MJ, Millan D, Kaye SB, et al: Mismatch repair protein immunohistochemistry in ovarian cancer. Br J Cancer 78:27, 1998 (suppl 1)
33. Anthoney DA, McDwrath AJ, Gallagher WM, et al: Microsatellite instability, apoptosis and loss of p53 function in drug resistant tumor cells. Cancer Res 56:1374-1381, 1996
34. Kinsel LB, Szabo E, Greene GL, et al: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49:1052-1056, 1989
35. Frassoldati A, Adami F, Banzi C, et al: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44:185-192, 1997
36. Daidone MG, Silvestrini R, Luisi A, et al: Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 61:301-305, 1995
37. Linn SC, Pinedo HM, van ArkOtte J, et al: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71:787-795, 1997
38. Paulson TG, Wright FA, Parker BA, et al: Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 56:4021-4026, 1996
39. Bubb VJ, Curtis LJ, Cunningham C, et al: Microsatellite instability and the role of hmsh2 in sporadic colorectal cancer. Oncogene 12:2641-2649, 1996
40. Duckett DR, Drummond JT, Murchie AIH, et al: Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93:6443-6446, 1996
41. Yamada M, O'Regan E, Brown R, et al: Selective recognition of a cisplatin-DNA adduct by human MMR proteins. Nucleic Acids Res 25:491-495, 1997
42. Karran P, Hampson R: Genomic instability and tolerance to alkylating agents. Cancer Surv 28:69-85, 1996
43. Chen AY, Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol 34:191-218, 1994
44. Skladanowski A, Konopa J: Interstrand DNA cross-linking induced by anthracyclines in tumor cells. Biochem Pharmacol 47:2269-2278, 1994